Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human dose-escalation and dose-expansion study of JNJ-88998377 in relapsed/refractory B-cell non-Hodgkin lymphoma
jRCT2031240200Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of JNJ-88998377 in mature B-cell lymphoma and B-cell non-Hodgkin lymphoma (B-NHL) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of participants with adverse events and Number of participants with dose-limiting toxicities. Started Aug 2024; status: recruiting.
02
Drugs
JNJ-88998377
03
Conditions
mature B-cell lymphomaB-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on jRCT2031240200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240200.